

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-35. (Cancelled)

36. (Currently amended) A composition comprising:

a therapeutic component comprising an alpha-2 adrenergic agonist in a therapeutically effective amount, and an efficacy enhancing component ~~including~~ a prostanoid, ~~the efficacy enhancing component being provided in an effective amount greater than 0.2% (w/v) and less than about 10% (w/v) and being effective~~ to enhance the pharmacokinetic disposition of the therapeutic component and to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, the efficacy enhancing component being present ~~in-a-as an ion-pair~~ complex with the therapeutic component, the ion-pair complex remaining substantially intact in an aqueous environment, each of the enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component.

37. (Previously presented) A composition of claim 36 wherein the efficacy enhancing component is present in an amount effective to enhance the permeability of the therapeutic component relative to the permeability of the therapeutic component without the efficacy enhancing component.

38. (Cancelled)

39. (Currently amended) A composition of claim 36 [[38]] wherein the alpha-2-adrenergic component agonist comprises a quinoxaline component.

40. (Previously presented) A composition of claim 39 wherein the quinoxaline component is selected from the group consisting of quinoxalines, salts thereof, and mixtures thereof.

41. (Currently amended) A composition of claim 36 wherein the therapeutic component further comprises a component [[is]] selected from the group consisting of N-methyl-D-aspartate antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

42. (Cancelled)

43. (Currently amended) A composition of claim 36 wherein the efficacy enhancing component further comprises a fatty acid selected from the group consisting of saturated fatty acids and unsaturated fatty acids, and mixtures thereof.

44. (Currently amended) A composition of claim 36 wherein the efficacy enhancing component ~~further~~ comprises a fatty acid with more than 12 carbon atoms per molecule.

45. (Currently amended) A composition of claim 36 wherein the efficacy enhancing component ~~further~~ comprises a docosahexanoic acid.

46. (Currently amended) A composition of claim 36 wherein the efficacy enhancing component ~~further~~ comprises a linolenic linoleic acid.

47. (Previously presented) A composition of claim 36 wherein the efficacy enhancing component has a therapeutic effect.

48. (Previously presented) A composition of claim 36 wherein the efficacy enhancing component is therapeutically active when complexed with the therapeutic component.

49. (Previously presented) A composition of claim 36 wherein the efficacy enhancing component is therapeutically active when the efficacy enhancing component is not complexed with the therapeutic component.

50. (Previously presented) A composition of claim 36 wherein the efficacy enhancing component is effective to reduce intraocular pressure when the composition is administered to the eye.

51. (Cancelled)

52. (Cancelled)

53. (Previously presented) A composition of claim 36 wherein the complex is insoluble.

54. (Previously presented) A composition of claim 36 wherein the complex is dissociable in a biological environment to provide a therapeutic effect.

55. (Previously presented) A composition of claim 36 which includes at least one additional therapeutic component and the efficacy enhancing component is complexed with both the therapeutic component and the additional therapeutic component.

56. (Previously presented) A composition of claim 36 wherein a single therapeutic component is present in the complex with more than one efficacy enhancing component.

57. (Previously presented) A composition of claim 36 which is ophthalmically acceptable.

58. (Previously presented) A composition of claim 36 which further comprises a carrier.

59. (Currently amended) A composition comprising:  
an adrenergic agonist; and  
an efficacy enhancing component provided in an amount effective to form an ion-pair complex with the adrenergic agonist, the complex substantially remains intact in a high dielectric constant solvent a fatty acid selected from the group

~~consisting of docosahexanoic acids, linolenic acids, and mixtures thereof,~~

~~wherein the adrenergic agonist is present in a complex with the fatty acid, the complex substantially remains intact in an aqueous environment.~~

60. (Currently amended) A composition comprising:

an ion-pair complex including a therapeutic component comprising an adrenergic agonist, and an efficacy enhancing component, wherein the efficacy enhancing component is selected from the group consisting of anionic polymers, fatty acids, and mixtures thereof, and is present in an amount greater than 0.2% (w/v) and less than about 10% (w/v) and being effective to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, each of the enhanced effects being relative to the effect obtained with the therapeutic component without the efficacy enhancing component; and

a carrier component which includes saline.

61. (Previously presented) A composition of claim 60 wherein the therapeutic component comprises an alpha-2-adrenergic agonist.

62. (Previously presented) A composition of claim 61 wherein the alpha-2-adrenergic agonist includes a quinoxaline component.

63. (Previously presented) A composition of claim 62 wherein the quinoxaline component is selected from the group consisting of quinoxalines, salts thereof, and mixtures thereof.

64. (Currently amended) The composition of claim 60 wherein the therapeutic component [[is]] further comprises a second component selected from the group consisting of N-methyl-D-aspartate antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

65. (Previously presented) A composition of claim 60 which has a pH of about 7 or greater.

66. (Previously presented) A composition of claim 60 which has a pH in a range of about 7 to about 9.

67. (Cancelled)

68. (Previously presented) A composition of claim 60 which is ophthalmically acceptable.

69. (Cancelled)

70. (Previously presented) The composition of claim 39, wherein the quinoxaline component is selected from the group consisting of (2-imidazolin-2-ylamino) quinoxalines, salts thereof, and mixtures thereof.

71. (Previously presented) The composition of claim 39, wherein the quinoxaline component is selected from the group consisting of 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline, salts thereof, and mixtures thereof.

72. (Previously presented) The composition of claim 62, wherein the quinoxaline component is selected from the group consisting of (2-imidazolin-2-ylamino) quinoxalines, salts thereof, and mixtures thereof. /

73. (Previously presented) The composition of claim 62, wherein the quinoxaline component is selected from the group consisting of 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline, salts thereof, and mixtures thereof.

74. (Currently amended) A composition comprising:

a therapeutic component in a therapeutically effective amount, the therapeutic component comprising a 5-bromo-6-(2-imidazolin-2-ylamino) quinoxaline, and

an efficacy enhancing component comprising a linoleic acid component selected from the group consisting of deosahexanoic acids, linolenic acids, prostaglandins, and mixtures thereof, the efficacy enhancing component provided in an effective amount to enhance the pharmacokinetic disposition of the therapeutic component and to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, the efficacy enhancing component being present in a complex with the therapeutic component, the complex remaining substantially intact in an aqueous environment, each of enhanced effects being relative to

the effect obtained with the therapeutic component without the efficacy enhancing component.

75. (Previously presented) The composition of claim 74, further comprising at least one additional therapeutic component selected from the group consisting of N-methyl-D-aspartate antagonists, antibacterials, antihistamines, decongestants, antiinflammatories, antiparasitics, miotics, anticholinergics, adrenergics, alpha-2-adrenergic agonists, antivirals, local anesthetics, antifungals, amoebicidals, trichomonocidals, analgesics, mydriatics, antiglaucoma drugs, carbonic anhydrase inhibitors, ophthalmic diagnostic agents, ophthalmic agents used as adjuvants in surgery, chelating agents, antineoplastics, antihypertensives, muscle relaxants, diagnostics, and mixtures thereof.

76. (Previously presented) The composition of claim 73, which has a pH of about 7 or greater.

77. (Previously presented) The composition of claim 73, further comprising at least one additional efficacy enhancing component selected from the group consisting saturated fatty acids and unsaturated fatty acids, and mixtures thereof.

78. (New) A liquid composition comprising:

a therapeutic component in a therapeutically effective amount, and

an efficacy enhancing component provided in an amount effective to enhance the pharmacokinetic disposition of the therapeutic component and to enhance the movement of the therapeutic component across a lipid membrane, or a biological membrane under physiological conditions, the efficacy enhancing component being present as a complex with the therapeutic component, the complex remaining substantially intact in an aqueous environment,

wherein the liquid composition comprising the complex has a reduced osmotic pressure relative to a substantially identical liquid composition in which the therapeutic component is not complexed with the efficacy enhancing component.

79. (New) The composition of claim 78, wherein the therapeutic component comprises a plurality of different therapeutically effective agents.

80. (New) The composition of claim 78, wherein the efficacy enhancing component comprises an anionic polymer.

81. (New) The composition of claim 78, wherein the therapeutic component and the efficacy enhancing component are provided in saline.

82. (New) The composition of claim 78, wherein the therapeutic component and the efficacy enhancing component form an ion-pair complex.

83. (New) The composition of claim 78, wherein the therapeutic component comprises an adrenergic agonist.

84. (New) The composition of claim 78, wherein the efficacy enhancing component comprises a fatty acid.

85. (New) The composition of claim 78, wherein the composition comprises a single therapeutic component and a plurality of different efficacy enhancing components.

86. (New) The composition of claim 78, wherein the composition comprises a plurality of different therapeutic components and a single efficacy enhancing component.